4.5 Article

Enhancing heterologous protection in pigs vaccinated with chimeric porcine reproductive and respiratory syndrome virus containing the full-length sequences of shuffled structural genes of multiple heterologous strains

期刊

VACCINE
卷 35, 期 18, 页码 2427-2434

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2017.03.046

关键词

Porcine reproductive and respiratory syndrome virus (PRRSV); Vaccine; DNA shuffling; Cross-protection; Heterologous strains; RFLP 1-7-4

资金

  1. Virginia Tech
  2. Biotechnology and Biological Sciences Research Council [BBS/E/D/20241866, BBS/E/D/20241864, BBS/E/D/20002174, BBS/E/D/20241865] Funding Source: researchfish
  3. BBSRC [BBS/E/D/20241865, BBS/E/D/20241866, BBS/E/D/20002174, BBS/E/D/20241864] Funding Source: UKRI

向作者/读者索取更多资源

Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of arguably the most economically important global swine disease. The extensive genetic variation of PRRSV strains is a major obstacle for heterologous protection of current vaccines. Previously, we constructed a panel of chimeric viruses containing only the ectodomain sequences of DNA-shuffled structural genes of different PRRSV strains in the backbone of a commercial vaccine, and found that one chimeric virus had an improved cross-protection efficacy. In this present study, to further enhance the cross-protective efficacy against heterologous strains, we constructed a novel chimeric virus VR2385-S3456 containing the full-length sequences of shuffled structural genes (ORFs 3-6) from 6 heterologous PRRSV strains in the backbone of PRRSV strain VR2385. We showed that the chimeric virus VR2385-S3456 induced a high level of neutralizing antibodies in pigs against two heterologous strains. A subsequent vaccination and challenge study in 48 pigs revealed that the chimeric virus VR2385-S3456 conferred an enhanced cross protection when challenged with heterologous virus strain NADC20 or a contemporary heterologous strain RFLP 1-7-4. The results suggest that the chimera VR2385-S3456 may be a good PRRSV vaccine candidate for further development to confer heterologous protection. (C) 2017 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据